SG193379A1 - Dosing regimens for the treatment of fabry disease - Google Patents

Dosing regimens for the treatment of fabry disease Download PDF

Info

Publication number
SG193379A1
SG193379A1 SG2013067954A SG2013067954A SG193379A1 SG 193379 A1 SG193379 A1 SG 193379A1 SG 2013067954 A SG2013067954 A SG 2013067954A SG 2013067954 A SG2013067954 A SG 2013067954A SG 193379 A1 SG193379 A1 SG 193379A1
Authority
SG
Singapore
Prior art keywords
gal
agalsidase
migalastat
deoxygalactonojirimycin
infusion
Prior art date
Application number
SG2013067954A
Other languages
English (en)
Inventor
Douglas Stuart Greene
Kenneth Joseph Valenzano
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46831259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG193379(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of SG193379A1 publication Critical patent/SG193379A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01062—Glycosylceramidase (3.2.1.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
SG2013067954A 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease SG193379A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161451798P 2011-03-11 2011-03-11
US201161578201P 2011-12-20 2011-12-20
US201261596165P 2012-02-07 2012-02-07
PCT/US2012/028260 WO2012125402A2 (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease

Publications (1)

Publication Number Publication Date
SG193379A1 true SG193379A1 (en) 2013-10-30

Family

ID=46831259

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201604757RA SG10201604757RA (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease
SG2013067954A SG193379A1 (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201604757RA SG10201604757RA (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease

Country Status (16)

Country Link
US (4) US20140219986A1 (enExample)
EP (2) EP2683382B1 (enExample)
JP (5) JP2014528901A (enExample)
KR (1) KR20140011367A (enExample)
CN (2) CN107088225A (enExample)
AU (6) AU2012229330B2 (enExample)
CA (1) CA2829947C (enExample)
CL (1) CL2013002601A1 (enExample)
EA (1) EA031874B1 (enExample)
ES (1) ES2807502T3 (enExample)
HK (1) HK1242998A1 (enExample)
MX (1) MX2013010446A (enExample)
SG (2) SG10201604757RA (enExample)
TW (3) TWI624259B (enExample)
WO (1) WO2012125402A2 (enExample)
ZA (1) ZA201306735B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3457135T3 (fi) 2006-05-16 2025-03-08 Amicus Therapeutics Inc Fabryn taudin hoitovaihtoehtoja
HUE026543T2 (hu) 2008-02-12 2016-06-28 Amicus Therapeutics Inc Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
AU2014249224B2 (en) 2013-03-11 2019-01-17 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
AU2015216909B2 (en) * 2014-02-17 2017-07-20 Glaxosmithkline Intellectual Property Development Limited Microbiological process
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
GB201508025D0 (en) * 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3335126A4 (en) 2015-08-11 2019-05-01 Cognoa, Inc. METHOD AND DEVICE FOR DETERMINING DEVELOPMENT PROGRESS WITH ARTIFICIAL INTELLIGENCE AND USER ENTRY
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
WO2017165164A1 (en) * 2016-03-22 2017-09-28 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
CA3031249A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naive and ert-experienced patients
CN110192252A (zh) 2016-11-14 2019-08-30 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
EP3580700A4 (en) * 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
BR112019025083B1 (pt) 2017-05-30 2022-08-09 Amicus Therapeutics, Inc Métodos de tratamento de pacientes portadores de fabry com insuficiência renal
TWI795408B (zh) * 2017-05-30 2023-03-11 美商阿米庫斯醫療股份有限公司 治療有腎損傷的法布里患者的方法
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
CA3090496C (en) * 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
PL3840753T3 (pl) * 2018-08-20 2025-01-20 Amicus Therapeutics, Inc. Migalastat do zastosowania w sposobach leczenia choroby fabry'ego u pacjentów mających mutację w genie gla
KR102785528B1 (ko) 2019-03-22 2025-03-21 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
AU2020253455A1 (en) 2019-04-03 2021-11-04 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation
AR120055A1 (es) * 2019-06-11 2022-02-02 Amicus Therapeutics Inc Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
CA3147055A1 (en) 2019-08-07 2021-02-11 Elfrida Benjamin Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20240197706A1 (en) * 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PT2444102E (pt) * 2003-01-31 2015-09-17 Sinai School Medicine Terapia combinada para o tratamento de distúrbios de deficiência proteica
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100457106C (zh) * 2005-06-15 2009-02-04 同济大学 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用
FI3457135T3 (fi) * 2006-05-16 2025-03-08 Amicus Therapeutics Inc Fabryn taudin hoitovaihtoehtoja
WO2008121826A2 (en) * 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20100291060A1 (en) * 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a

Also Published As

Publication number Publication date
WO2012125402A2 (en) 2012-09-20
WO2012125402A3 (en) 2014-05-01
AU2012229330B2 (en) 2016-04-21
EP2683382A4 (en) 2014-10-22
JP2021098697A (ja) 2021-07-01
US20180153999A1 (en) 2018-06-07
CL2013002601A1 (es) 2014-03-28
EP2683382B1 (en) 2020-04-22
ES2807502T3 (es) 2021-02-23
AU2024205251A1 (en) 2024-08-22
JP2017132780A (ja) 2017-08-03
ZA201306735B (en) 2014-07-30
CA2829947A1 (en) 2012-09-20
KR20140011367A (ko) 2014-01-28
SG10201604757RA (en) 2016-08-30
AU2016204445B2 (en) 2018-03-22
EA031874B1 (ru) 2019-03-29
JP2023093448A (ja) 2023-07-04
TW201302197A (zh) 2013-01-16
AU2016204445A1 (en) 2016-07-21
CA2829947C (en) 2019-01-15
MX2013010446A (es) 2014-03-27
TWI624259B (zh) 2018-05-21
TW201634048A (zh) 2016-10-01
AU2012229330A1 (en) 2013-10-03
AU2022203011A1 (en) 2022-05-26
CN103974619B (zh) 2017-02-15
CN107088225A (zh) 2017-08-25
US20200268890A1 (en) 2020-08-27
AU2018201637A1 (en) 2018-04-05
EA201301018A1 (ru) 2014-04-30
AU2020201715A1 (en) 2020-04-09
JP2020033360A (ja) 2020-03-05
TW201740945A (zh) 2017-12-01
EP2683382A2 (en) 2014-01-15
NZ615726A (en) 2015-01-30
US20140219986A1 (en) 2014-08-07
TWI624258B (zh) 2018-05-21
JP2014528901A (ja) 2014-10-30
US20240115708A1 (en) 2024-04-11
EP3698792A1 (en) 2020-08-26
CN103974619A (zh) 2014-08-06
HK1242998A1 (zh) 2018-07-06

Similar Documents

Publication Publication Date Title
US20240115708A1 (en) Dosing Regimens For The Treatment Of Fabry Disease
EP3871688B1 (en) Dosing regimens for the treatment of pompe disease
HK40036814A (en) Dosing regimens for the treatment of fabry disease
NZ615726B2 (en) Dosing regimens for the treatment of fabry disease
HK40058710A (en) Dosing regimens for the treatment of pompe disease
HK40112795A (en) Dosing regimens for the treatment of pompe disease
HK40058710B (en) Dosing regimens for the treatment of pompe disease